REGARD: A phase 3, randomized, double-blind trial of ramucirumab (RAM) and best supportive care (BSC) versus placebo (PL) and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression (PD) on first-line platinum- and/or fluoropyrimidine-containing combination therapy: Age subgroup analysis.

被引：3
|
作者：
Fuchs, Charles S.
Tomasek, Jiri
Cho, Jae Yong
Tomasello, Gianluca
Goswami, Chanchal
dos Santos, Lucas Vieira
Aprile, Giuseppe
Ferry, David
Melichar, Bohuslav
Tehfe, Mustapha Ali
Tehfe, All
Topuzov, Eldar
Zalcberg, John Raymond
Chau, Ian
Tabernero, Josep
Hsu, Yanzhi
Schwartz, Jonathan D.
Koshiji, Minori
Safran, Howard
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Masaryk Univ, Fac Med, Masaryk Mem Canc Inst, Brno, Czech Republic
[3] Gangnam Severance Hosp, Seoul, South Korea
[4] Ist Ospitalieri Cremona, Cremona, Italy
[5] BP Poddar Hosp, Kolkata, India
[6] Med Res Ltd, Kolkata, India
[7] Univ Campinas UNICAMP, Sao Paulo, Brazil
[8] Azienda Osped Univ, Udine, Italy
[9] New Cross Hosp, Wolverhampton, England
[10] Palacky Univ, Med Sch & Teaching Hosp, CR-77147 Olomouc, Czech Republic
[11] Hop Notre Dame CHUM, Montreal, PQ, Canada
[12] Peter MacCallum Canc Ctr, Melbourne, Australia
[13] Royal Marsden NHS Fdn Trust, London, England
[14] Royal Marsden NHS Fdn Trust, Surrey, England
[15] Vall dHebron Univ Hosp, Barcelona, Spain
[16] ImClone Syst, Bridgewater, NJ USA
[17] ImClone Syst, Branchburg, NJ USA
[18] ImClone Syst, Kobe, Hyogo, Japan
[19] Brown Univ, Oncol Res Grp, Providence, RI 02912 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.4057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4057
引用
收藏
页数：1
相关论文
共 25 条
  • [1] REGARD: A phase III, randomized, double-blind trial of ramucirumab and best supportive care (BSC) versus placebo and BSC in the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line p
    Fuchs, Charles S.
    Tomasek, Jiri
    Cho, Jae Yong
    Filip, Dumitru
    Passalacqua, Rodolfo
    Goswami, Chancal
    Safran, Howard
    Dos Santos, Lucas Vieira
    Aprile, Giuseppe
    Ferry, David
    Melichar, Bohuslav
    Tehfe, Moustapha
    Topuzov, Eldar
    Tabernero, Josep
    Raymond Zalcberg, John
    Chau, Ian
    Koshiji, Minori
    Hsu, Yanzhi
    Schwartz, Jonathan
    Ajani, Jaffer
    CANCER RESEARCH, 2013, 73 (08)
  • [2] RAINBOW: A GLOBAL, PHASE 3, DOUBLE-BLIND STUDY OF RAMUCIRUMAB (RAM) PLUS PACLITAXEL (PTX) VERSUS PLACEBO (PL) plus PTX IN THE TREATMENT OF ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA FOLLOWING DISEASE PROGRESSION ON FIRST-LINE PLATINUM- AND FLUOROPYRIMIDINE-CONTAINING COMBINATION THERAPY: A SUBGROUP ANALYSIS OF WESTERN POPULATION
    Wilke, Hansjochen
    Clingan, Philip
    Ananda, Sumi
    Kurteva, Galina
    Suuroja, Tiit
    Folprecht, Gunnar
    Beny, Alexander
    Pastorelli, Davide
    Cesas, Alvydas
    Nowecki, Zbigniew
    Toganel, Cornelia
    Bodoky, Gyoergy
    Lipatov, Oleg
    Miron, Maria Limon
    Cunningham, David
    Cummins, Sebastian
    Wainberg, Zev
    Ko, Andrew
    Emig, Michael
    Chandrawansa, Kumari
    van Cutsem, Eric
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 171 - 171
  • [3] RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy-An age-group analysis
    Muro, Kei
    Bodoky, Gyorgy
    Cesas, Alvydas
    Chao, Yee
    Clingan, Philip
    Hironaka, Shuichi
    Komatsu, Yoshito
    Kurteva, Galina Petrova
    Lipatov, Oleg N.
    Nishina, Tomohiro
    Oh, Sang Cheul
    Ohtsu, Atsushi
    Shimada, Yasuhiro
    Sugimoto, Naotoshi
    Van Cutsem, Eric
    Carlesi, Roberto
    Chandrawansa, Kumari
    Wilke, Hansjochen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
    Kensei Yamaguchi
    Kazumasa Fujitani
    Fumio Nagashima
    Yasushi Omuro
    Nozomu Machida
    Tomohiro Nishina
    Toshiko Koue
    Mika Tsujimoto
    Kaijiro Maeda
    Taroh Satoh
    Gastric Cancer, 2018, 21 : 1041 - 1049
  • [5] Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study
    Yamaguchi, Kensei
    Fujitani, Kazumasa
    Nagashima, Fumio
    Omuro, Yasushi
    Machida, Nozomu
    Nishina, Tomohiro
    Koue, Toshiko
    Tsujimoto, Mika
    Maeda, Kaijiro
    Satoh, Taroh
    GASTRIC CANCER, 2018, 21 (06) : 1041 - 1049
  • [6] REGARD phase III, randon ed, double-blinded trial of mum ib and best supportive care (BSC) versus placebo and BSC in the Ireattneiti of metasta lie gastric or gastroesophageal junction (GEJ) adenocarcino u following disease progression on first-line platinum- and/or fluorop., midine-containing combination therapy.
    Fuchs, Charles S.
    Tomasek, Jiri
    Cho, Jae Yong
    Dumitru, Filip
    Passalacqua, Rodolfo
    Goswami, Chanchal
    Safran, Howard
    dos Santos, Lucas Vieira
    Aprile, Giuseppe
    Ferry, David R.
    Melichar, Bohuslav
    Tehfe, Mustapha
    Topuzov, Eldar
    Tabemero, Josep
    Zalcberg, John Raymond
    Chau, Ian
    Koshiji, Minori
    Hsu, Yanzhi
    Schwartz, Jonathan D.
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [7] RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum-and fluoropyrimidine-containing combination therapy-Efficacy analysis in Japanese and Western patients.
    Hironaka, Shuichi
    Shimada, Yasuhiro
    Sugimoto, Naotoshi
    Komatsu, Yoshito
    Nishina, Tomohiro
    Yamaguchi, Kensei
    Segawa, Yoshihiko
    Omuro, Yasushi
    Tamura, Takao
    Doi, Toshihiko
    Yukisawa, Seigo
    Yasui, Hirofumi
    Nagashima, Fumio
    Gotoh, Masahiro
    Esaki, Taito
    Emig, Michael
    Chandrawansa, Kumari
    Muro, Kei
    Wilke, Hansjochen
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE)
    Wilke, Hansjochen
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg N.
    Kim, Tae-You
    Cunningham, David
    Ohtsu, Atsushi
    Rougier, Philippe
    Emig, Michael
    Carlesi, Roberto
    Chandrawansa, Kumari
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [9] RAINBOW: A global, phase 3, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy: Results of a multiple Cox regression analysis adjusting for prognostic factors.
    Wilke, Hansjochen
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Sugimoto, Naotoshi
    Lipatov, Oleg N.
    Kim, Tae-You
    Cunningham, David
    Rougier, Philippe
    Emig, Michael
    Carlesi, Roberto
    Chandrawansa, Kumari
    Muro, Kei
    Ohtsu, Atsushi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.
    Xu, Rui-hua
    Zhang, Yan-Qiao
    Pan, Hongming
    Feng, Ji Feng
    Zhang, Tao
    Liu, Tianshu
    Qin, Yanru
    Han, Rubing
    Zhang, Wanli
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
123